Tilray Brands, Inc. reported results
SEC 8-KRead source ↗
Tilray Brands, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in May.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Tilray Brands, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders3 buying, 1 selling3 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
- Funds102 adding, 74 cuttingOf 14 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 86% in the quarter to 2026-08-31.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Tilray Brands, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 81% and a beta of 1.5 against the S&P 500.
- Heavily shorted. 14.8% of the shares available to trade are sold short (5.2 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
- Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 80.8% over 90 days.
Latest results
- Earnings per share
- -$0.02 against an average estimate of -$0.14: beat by 85.7%
- Share reaction
- -4.8% in the first session after the results on October 8, 2026, against +0.2% for the S&P 500
- Next report
- January 7, 2027; average EPS estimate $0.00
Price chart
- 1 day+0.8%
- 1 week-6.3%
- 1 month-29.4%
- This year-71.8%
- 1 year-81.0%
- 5 years-97.7%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- October 8, 2026
- Next results (est.)
- January 7, 2027
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
- Share issue
Tilray Brands, Inc. sold unregistered shares
SEC 8-KRead source ↗ - Share issue
Tilray Brands, Inc. sold unregistered shares
SEC 8-KRead source ↗ - Results
Tilray Brands, Inc. reported results
SEC 8-KRead source ↗
Valuation models
We value Tilray Brands, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tilray Brands, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: January 7, 2027, before the open. Analysts expect revenue of $265m and EPS of $0.00 (range $0.00 to $0.00) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.13 | −217% | $1.1bn | +20% |
| Next | $0.14 | +210% | $1.2bn | +5% |
Next year's EPS estimate has moved −80.8% in 90 days, across 2 analysts.
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −150.2% on 90 days ago. In the last 30 days, 0 analysts raised Tilray Brands, Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $0.26 | $0.74 |
| 60 days ago | $0.26 | $0.45 |
| 30 days ago | $0.07 | $0.18 |
| 7 days ago | $0.06 | $0.18 |
| Now | −$0.13 | $0.14 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.14 | −$0.02 | +85.7% |
| May 2026 | $0.21 | $0.05 | −76.2% |
| Feb 2026 | $0.07 | $0.02 | −71.4% |
| Nov 2025 | $0.00 | −$0.02 | 0.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 14.8% of tradable shares
- Days to cover
- 5.15 at average volume
- Short interest, 1 month
- +11% to October 15, 2026
- Held by institutions
- 10% of shares
- Held by insiders
- 1.6% of shares
- Employees
- 3,595 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| TLRY | −15% | −62% | −15% | −42% | −32% | −72% |
| Industry peers (median) | −20% | −49% | −13% | −2% | +9% | −12% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| TLRY | 25% | 42% | 42% | 25% | 33% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| TLRY | −89% | −70% | −55% | −59% | −75% | −74% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since July 19, 2018: 100% from September 19, 2018 to October 30, 2026. Getting back needed a 84509% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $2.53 – $13.94
- From 52-week high
- −81.7%
- vs 50-day average
- −31.9%
- vs 200-day average
- −53.1%
- Volatility (1 year)
- 81%
- Beta vs S&P 500
- 1.47
Share price after results
- Next day
- 3 up, 9 down typical move ±7.8%
- After a week
- 3 up, 9 down typical move ±12.1%
- After a month
- 2 up, 9 down typical move ±25.9%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| October 8, 2026 | −4.8% | +0.2% | −13.7% | — |
| July 28, 2026 | −1.0% | −1.3% | +15.1% | +15.1% |
| April 1, 2026 | +1.2% | +0.8% | +3.9% | −4.8% |
| January 8, 2026 | +2.1% | +0.7% | +8.0% | −14.3% |
| October 9, 2025 | 0.0% | −3.0% | −10.5% | −27.9% |
| July 28, 2025 | −15.9% | −0.3% | −11.6% | +110.1% |
| April 8, 2025 | −8.6% | +8.8% | −19.0% | −24.1% |
| January 10, 2025 | −13.9% | −1.4% | −12.4% | −31.4% |
| October 10, 2024 | 0.0% | +0.4% | −3.7% | −8.6% |
| July 29, 2024 | +9.8% | −0.4% | −5.5% | −4.4% |
| April 9, 2024 | −22.0% | −0.9% | −29.3% | −24.7% |
| January 9, 2024 | −14.5% | +0.4% | −12.0% | −19.2% |
Fundamentals
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Cannabis | $352M | ▲ 6.6% |
| Distribution Business | $327M | ▲ 20.7% |
| Beverage Alcohol Business | $265M | ▲ 4.8% |
| Wellness Business | $65.9M | ▲ 8.9% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| EMEA | $446M | 48.7% | ▲ 37.8% |
| United States | $242M | 26.5% | ▼ 11.4% |
| Canada | $216M | 23.6% | ▲ 1.3% |
| Rest of World | $11.7M | 1.3% | ▲ 2.6% |
From Tilray Brands, Inc.'s 10-K filed July 28, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Who owns it
Funds buying and selling- Reported value
- $62.9M
- Institutions reporting
- 234
- Shares held vs prior quarter
- ▲ 35.6%
- Positions opened / closed
- 43 / 20
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Tidal Investments LLC | $11.2M | 2.5M | 17.8% | ▼ 2.5% |
| Susquehanna International Group, LLP | $4.6M | 1.0M | 7.3% | ▲ 88.4% |
| Morgan Stanley | $4.5M | 995K | 7.1% | ▲ 55.2% |
| Citadel Advisors LLC | $3.9M | 868K | 6.2% | ▲ 6142.1% |
| Point72 Asset Management, L.P. | $2.9M | 649K | 4.6% | New |
| Mirae Asset Global Etfs Holdings Ltd. | $2.9M | 647K | 4.6% | ▲ 32.9% |
| AQR Capital Management LLC | $2.3M | 513K | 3.7% | ▲ 14.5% |
| Blackrock, Inc. | $2.1M | 462K | 3.3% | ▲ 9.2% |
| UBS Group AG | $2M | 454K | 3.2% | ▼ 30.4% |
| Lazard Asset Management LLC | $1.8M | 395K | 2.8% | New |
| State Street Corp | $1.7M | 384K | 2.7% | ▲ 54.9% |
| Vanguard Portfolio Management LLC | $1.6M | 349K | 2.5% | ▼ 0.1% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tilray Brands, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $69,225 3 trades by 3 insiders, last 12 months Insider sales History → $232,879 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $163,654 net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Gendel Mitchell Global General Counsel | August 6, 2026 | Buy | 2,500 | $4.43 | $11,075 |
| Merton Carl A Chief Financial Officer | August 4, 2026 | Buy | 10,000 | $4.62 | $46,200 |
| Faltischek Denise M Chief Strategy Officer | August 3, 2026 | Buy | 2,500 | $4.78 | $11,950 |
| Hopkinson David G. Director | April 21, 2026 | Sell | 33,556 | $6.94 | $232,879 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Trades by members of Congress
All 13 trades and filingsNo trades in Tilray Brands, Inc. disclosed in the last 12 months; 13 earlier trades on record.
- Brian J. MastSale (full), $1,001 - $15,000, traded April 18, 2022, filed May 9, 2022
- Brian J. MastExchange, $1,001 - $15,000, traded May 3, 2021, filed October 5, 2022
- John A. YarmuthPurchase, $1,001 - $15,000, traded February 12, 2021, filed February 19, 2021
Earnings dates and SEC filings
Results announcements
Next expected around January 7, 2027 estimated from the company's past filing pattern, not announced
- October 8, 2026
- July 28, 2026
- April 1, 2026
- January 8, 2026
- October 9, 2025
- July 28, 2025
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Tilray Brands, Inc. in brief
- What does Tilray Brands, Inc. do?
- Tilray Brands, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in May.
- What is Tilray Brands, Inc.'s stock ticker?
- Tilray Brands, Inc. trades under the ticker TLRY on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Tilray Brands, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Tidal Investments LLC, Susquehanna International Group, LLP and Morgan Stanley. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Tilray Brands, Inc. stock?
- Over the last 12 months, Tilray Brands, Inc.'s directors and officers reported 3 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
- When is Tilray Brands, Inc.'s next earnings date?
- Around January 7, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tilray Brands, Inc. announces its own schedule.
Follow research on Tilray Brands, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.